Concord Biotech Limited (BOM:543960)

Market Cap	166.35B
Revenue (ttm)	11.88B
Net Income (ttm)	3.56B
Shares Out	n/a
EPS (ttm)	34.03
PE Ratio	46.71
Forward PE	37.72
Dividend	10.70 (0.67%)
Ex-Dividend Date	Sep 3, 2025

Volume	2,172
Average Volume	17,589
Open	1,610.50
Previous Close	1,607.00
Day's Range	1,582.95 - 1,615.45
52-Week Range	1,370.05 - 2,451.65
Beta	n/a
RSI	43.02
Earnings Date	Nov 7, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,571
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.